IL6 and in situ carcinoma: While some in vitro and in vivo studies demonstrate a reduction in IL-6-associated cell proliferation, migration and invasion [87], others show elevated IL-6 to be associated with more advanced clinical stage (T2-T4 vs. T1 and CIS), higher recurrence rate following treatment, and shorter survival [88].